- Home
- RARE
as 05-17-2024 4:00pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 3.5B | IPO Year: | 2014 |
| Target Price: | $87.86 | AVG Volume (30 days): | 732.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.52 - $54.98 | Next Earning Date: | 05-02-2024 |
| Revenue: | $442,586,000 | Revenue Growth: | 15.29% |
| Revenue Growth (this year): | 20.53% | Revenue Growth (next year): | 25.86% |
Share on Social Networks:
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kassberg Thomas Richard | RARE | CBO & EVP | Mar 11 '24 | Sell | $49.93 | 11,509 | $574,644.37 | 252,823 | SEC Form 4 |
| Pinion John Richard | RARE | See Remarks | Mar 1 '24 | Sell | $53.76 | 4,173 | $224,340.48 | 89,268 | SEC Form 4 |
| Crombez Eric | RARE | EVP and Chief Medical Officer | Mar 1 '24 | Sell | $53.76 | 1,238 | $66,554.88 | 48,927 | SEC Form 4 |
| Kassberg Thomas Richard | RARE | CBO & EVP | Mar 1 '24 | Sell | $53.76 | 1,011 | $54,351.36 | 264,332 | SEC Form 4 |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Mar 1 '24 | Sell | $53.76 | 341 | $18,332.16 | 41,380 | SEC Form 4 |
| KAKKIS EMIL D | RARE | President & CEO | Dec 29 '23 | Sell | $47.87 | 30,000 | $1,436,100.00 | 569,770 | SEC Form 4 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
13 days ago
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
Insider Monkey
16 days ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Simply Wall St.
16 days ago
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
GuruFocus.com
17 days ago
Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
Zacks
17 days ago
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
GuruFocus.com
18 days ago
Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
Associated Press Finance
18 days ago